UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June

Commission File Number 1-15096

Serono S.A. ~~(Translation of registrant’s name into English)~~

~~15 bis, Chemin des Mines Case Postale 54 CH-1211 Geneva 20 Switzerland~~ (~~Address~~Translation of ~~principal~~ ~~executive~~registrant’s ~~office~~name into English)

~~Indicate~~15 bybis, ~~check~~Chemin ~~mark~~des ~~whether the registrant files or~~Mines ~~will~~Case ~~file~~Postale ~~annual reports under cover of Form 20~~54 CH-F1211 orGeneva ~~Form 40-F.~~20 Switzerland

~~Form 20-F x Form 40-F o~~(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .

Media Release

FOR IMMEDIATE RELEASE

COMPELLING EVIDENCEZYMOGENETICS OFAND RAPTIVAÒ 12-WEEK CLEARSERONO TRIALPRESENT DATA INPOSITIVE PATIENTSRESULTS WITHOF MODERATETACI-TO-SEVEREIG PLAQUEPHASE PSORIASIS1b PUBLISHEDTRIAL IN BRITISH JOURNALRHEUMATOID OFARTHRITIS DERMATOLOGYAT EULAR MEETING

~~The~~Phase ~~efficacy~~2 ~~and~~program ~~safety of RaptivaÒ were comparable between refractory patients and the more general moderate-~~to~~-severe~~ ~~plaque~~start ~~psoriasis~~later ~~patients~~this year

Seattle, USA and Geneva, Switzerland—, June 2226, 2006 — ZymoGenetics, Inc. (NASDAQ: ZGEN) and Serono (virt-x: SEO and NYSE: SRA) today announced ~~today that~~favorable ~~the~~results ~~12-week~~from ~~data~~a ~~from~~Phase ~~the~~1b clinical ~~study~~trial ~~CLEAR~~with TACI-Ig ~~(CLinical Experience~~in ~~Acquired~~73 patients with ~~RaptivaÒ~~rheumatoid arthritis (RA), recently ~~demonstrating~~presented ~~that~~at ~~RaptivaÒ~~the 7th ~~produced~~Annual European Congress of ~~significant~~Rheumatology ~~clinical~~(EULAR). TACI-Ig ~~improvements~~is ~~and~~a ~~was~~soluble ~~generally~~fusion ~~well~~protein ~~tolerated~~that ~~among~~neutralizes molecules ~~patients~~implicated ~~refractory,~~in ~~intolerant~~the orpathogenesis ~~contraindicated~~of several autoimmune diseases. TACI-Ig appeared to ~~systemic~~be ~~therapies~~well astolerated across the full range of dose levels and ~~well~~schedules tested. Clear biologic effect was observed as patients showed schedule and dose dependent decreases in the ~~total~~levels ~~population~~ of ~~patients~~immunoglobulin ~~with~~(Ig) ~~moderate-to-severe~~and serum ~~plaque~~rheumatoid factor levels. Although this study was not specifically ~~psoriasis~~designed to evaluate efficacy, ~~was~~encouraging ~~published~~trends were observed in ~~this~~ACR ~~month’s~~and ~~edition~~DAS 28 scores, commonly used measurements of clinical benefit. Based on these promising results, ZymoGenetics and Serono expect to begin the ~~British~~Phase ~~Journal~~2 clinical program of ~~Dermatology~~TACI-Ig in patients with RA in the second half of 2006.~~(1)~~

~~“Data~~In ~~from~~an ~~the~~oral presentation(1), ~~CLEAR~~Alain ~~study~~Munafo, ~~show~~Ph.D., ~~compelling~~Senior ~~evidence~~Scientific ofDirector ~~the benefit~~ of ~~RaptivaÒ not~~Serono, ~~only~~reported inthat ~~the~~TACI-Ig ~~general~~appeared ~~moderate-~~to~~-severe~~ ~~psoriasis~~be ~~patient~~well ~~population,~~tolerated ~~but also~~ in patients inwith moderate-to-severe ~~which~~RA. ~~previous~~The ~~treatments~~most ~~have~~common ~~failed~~adverse ~~due~~event towas ~~efficacy,~~a orgenerally inmild ~~whom~~injection ~~existing~~site ~~therapies~~reaction ~~cannot~~affecting beapproximately ~~prescribed~~40% ~~due~~of tothe ~~contraindications~~patients. orThere ~~safety~~were ~~concerns”,~~no ~~said~~serious ~~Franck~~adverse ~~Latrille,~~events ~~Senior~~reported. ~~Executive~~No ~~Vice~~patients ~~President,~~formed ~~Corporate~~detectable antibodies to ~~Global~~TACI-Ig, ~~Product~~and ~~Development~~the ofpatients’ ~~Serono.~~vaccination ~~“This~~immune ~~creates~~status adid ~~significant~~not ~~unmet~~appear ~~medical~~to be ~~need~~compromised ~~that~~by ~~RaptivaÒ is~~the ~~able to address~~drug.”

~~Following the 12~~TACI-~~week~~Ig ~~treatment, RaptivaÒ~~ demonstrated ~~a favorable~~clear ~~safety~~biological ~~profile~~activity, ~~and~~with ~~was~~schedule ~~clinically~~and ~~superior to placebo in showing a~~dose ~~statistically~~dependent ~~significantly~~reductions ~~higher PASI(2) 75 rate, the primary efficacy endpoint~~ of ~~the~~immunoglobulin ~~study.~~levels ~~793 patients were enrolled~~ in ~~this~~line ~~clinical~~with ~~trial, of which 526 comprised~~ the ~~refractory group. In the overall patient population,~~proposed ~~31.4%~~mechanism of ~~those~~action. ~~treated~~In ~~with RaptivaÒ reached~~ a ~~³ 75% PASI~~cohort ~~improvement,~~that ~~compared~~received toseven ~~4.2%~~doses of ~~patients~~TACI-Ig ~~treated~~over ~~with placebo (P <~~a ~~0.0001);~~three-month ~~in the refractory patient population~~period, ~~29.5%~~patients ~~versus 2.7% reached a PASI 75 rate (P < 0.0001).~~showed:

~~“Biological~~· Reductions ~~therapies are a major progress in the treatment~~ of ~~psoriasis, a frequent and disabling skin~~ ~~disease.~~several ~~RaptivaÒ is~~biomarkers ~~the~~typically ~~only~~found ~~EU approved biological molecule to specifically target T cells. The CLEAR study is of major importance as it prospectively demonstrates the efficacy and safety of RaptivaÒ~~ in ~~moderate-to-severe~~ ~~patients~~RA ~~as well as in~~ patients ~~who have little or no treatment options left available to them. The CLEAR study confirms the hope offered to our patients by this original therapeutic approach”~~, ~~said Louis Dubertret, professor and chairman of one of the leading global centers for Dermatology at the Hospital Saint Louis, Paris, and first author of this publication.~~including:

~~CLEAR is the first and currently only multinational~~o IgM, ~~randomized,~~IgA ~~double-blind,~~and ~~placebo-controlled,~~IgG ~~parallel-group~~reductions ~~trial demonstrating the efficacy~~ of ~~a biological therapy in an international patient population~~54%, ~~where~~37% ~~patients have previously failed to respond to other systemic therapies, or where these were inappropriate due to contraindications or intolerance. CLEAR prospectively~~ and ~~uniquely~~21% ~~demonstrates that RaptivaÒ is an effective therapy in moderate-to-severe plaque psoriasis patients regardless of previous systemic treatments.~~respectively;

~~(1) Dubertret~~o Reduction L,of ~~Sterry~~peripheral W,blood ~~Bos~~B-cell ~~JD,~~levels ~~Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA, CLEAR Multinational Study Group. Clinical experience acquired~~ with ~~the efalizumab (RaptivaÒ) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from~~ a ~~phase~~maximum ~~III~~decrease ~~international~~of ~~randomized, placebo~~30-~~controlled trial. Br J Dermatol 155:170–181.~~40%

~~(2) Psoriasis~~o 40-45% ~~Area~~reduction ~~and~~of ~~Severity~~IgM-RF, ~~Index;~~IgA-RF ~~most~~and ~~commonly used clinical scoring system to assess disease severity in clinical trials~~IgG-RF

1· Trends toward improvement of the ACR and DAS 28 scores commonly used to measure disease severity and effects of treatment.

~~Psoriasis is a debilitating chronic inflammatory skin~~(1) TACI-Ig ~~disease~~in ~~for~~patients ~~which~~with ~~there~~rheumatoid isarthritis ~~currently~~(RA): noan ~~permanent cure~~exploratory, ~~and patients require long~~multi-~~term treatment to control the disease. While various systemic therapies~~center, ~~and phototherapies are available~~double-blind, ~~treatment options are limited for many patients as these treatments potentially have serious side effects in the long~~placebo-~~term~~controlled, ~~management of the disease. In responding patients~~dose-escalating, ~~the~~single ~~biological agent~~and ~~RaptivaÒ offers~~repeat adose ~~new treatment paradigm for the~~phase ~~continuous~~1b ~~management~~study of(abstract ~~the disease~~OP0178), ~~increasing~~7th Annual ~~their~~European ~~quality~~Congress of ~~life~~Rheumatology (3EULAR)~~. Globally~~, ~~more~~June 21 ~~than~~- 3024,~~000~~ ~~patients have received Raptiva®~~2006, ~~both during clinical trials and post registration. This represents more than 17~~Amsterdam,~~500~~ ~~patient years of exposure, creating one of the largest existing databases of patients taking a biological therapy for psoriasis.~~Netherlands

~~###~~1

~~About~~In a separate poster presentation(2), Ivan Nestorov, Ph.D., Scientific Fellow of ZymoGenetics, reported that there was a well-defined relationship between TACI-Ig exposure and immunoglobulin response. IgM levels were found to be the ~~CLEAR~~most ~~Study~~responsive to TACI-Ig exposure, followed respectively by IgA and IgG levels. Dosing frequency seemed to play as important a role as dose level in the response of the three biomarkers.

~~CLEAR~~The ~~(CLinical Experience~~primary ~~Acquired~~objective ~~with~~of ~~RaptivaÒ) is~~ the ~~first~~Phase ~~multinational,~~1b ~~randomized,~~study ~~double~~was ~~blind, placebo-controlled,~~to ~~parallel-group~~determine ~~trial designed to evaluate~~ the safety and ~~efficacy~~tolerability of ~~RaptivaÒ compared~~TACI-Ig toin ~~placebo.~~RA ~~Patients~~patients ~~with moderate-~~and to~~-severe~~ ~~plaque~~examine the ~~psoriasis,~~relationship ~~including~~between ~~refractory~~TACI-Ig ~~patients,~~dose ~~defined~~and ~~as those~~schedule ~~for~~with ~~whom~~markers atof ~~least~~biologic ~~two~~and disease ~~systemic~~activity. ~~therapies~~The ~~were~~trial ~~unsuitable~~enrolled ~~because~~adult ofmale ~~lack of~~and ~~efficacy,~~female ~~intolerance~~patients ~~or contraindication~~with active, ~~were~~moderate-to-severe ~~randomized~~RA. inPatients areceived ~~2:1 ratio to~~single ~~receive~~or multiple doses of either ~~once~~TACI-Ig ~~weekly~~or placebo for 12a ~~weeks~~maximum ~~1mg/kg~~period ~~RaptivaÒ or~~of ~~placebo~~three months.

This prospective trial consisted of three periods: an initial 12-week double-blind treatment period, an observation period of up to 24 weeks and a 12-week open-label re-treatment period. The primary efficacy endpoint was the proportion of patients achieving ³ 75% PASI improvement at week 12. The secondary endpoints included changes in PASI, static Physician’s Global Assessment, Physician’s Global Assessment of change from baseline and percentage of body surface area affected.###

793 patients were included in this prospective trial, thereof 529 were randomized to RaptivaÒ and 264 to placebo. Amongst the 793 patients, 526 were refractory patients (342 randomized to RaptivaÒ and 184 to placebo). At week 12, RaptivaÒ achieved significantly higher PASI-75 rates in both, the refractory patients—29.5% for RaptivaÒ compared to 2.7% for placebo; (P< 0.0001)—and the overall study population—31.4% for RaptivaÒ versus 4.2% for placebo; (P < 0.0001). Superiority of RaptivaÒ to placebo was shown in both groups, the overall patient population and the refractory patients, for all secondary endpoints.Abstracts

Overall, the safety profile of RaptivaÒ in the initial 12 weeks of the CLEAR study is consistent with that reported in previous US phase III clinical studies. The incidenceabstracts of serious adverse events affecting the skin was 2.5% among efalizumab-treated patients and 2.3%presentation amongslides placebo-treatedare patients.available The frequencyat of serious arthritis-related adverse events was 0www.9% with efalizumab compared with 0zymogenetics.4%com within placebo. In the first“What’s 12New” weekssection ofon this study, adverse events considered potentially infection-related were reported 28.4% of efalizumab-treated patients and 20.1% of placebo-treated patients. No malignancies were reported and there were no reports of thrombocytopenia. The most frequently reported events in the CLEARhome study were headache, ‘influenza-like illness, arthralgia, rigor, pyrexia, nasopharyngitis, myalgia, and prurituspage.

~~Data on the 24-week~~Background ~~observation and 12-week re-treatment period were presented at the European Academy of Dermatology and Venerology in London, UK, in October 2005.(4)~~material

~~(3) Impact of~~For ~~efalizumab~~free ~~on patient~~B-~~reported~~roll, ~~outcomes~~video and inother ~~high-need~~content ~~psoriasis~~for ~~patients:~~Serono ~~results of~~and ~~the~~its ~~international~~products, ~~randomized,~~please ~~placebo-controlled~~visit ~~Phase~~the ~~III~~Serono ~~Clinical~~Media ~~Experience~~Center ~~Acquired~~www.thenewsmarket.com/Serono. ~~with~~You ~~Raptiva~~can ~~(CLEAR)~~download ~~trial,~~print-quality ~~Ortonne~~images Jand receive broadcast-Pstandard ~~et al.;~~video ~~BMC~~digitally or by tape from this site. ~~Dermatology~~Registration ~~2005,~~and ~~5:13~~video is free to the media.

~~(4) The safety~~About ~~of efalizumab in patients with moderate~~TACI-~~to-severe plaque psoriasis: results from the CLEAR study beyond 12 weeks, J. Ring, L. Dubertret, T. May, S. Chimenti & W. Sterry, JEADV (2005) 19 (Suppl. 2), 1–412 poster P06.87~~Ig

2ZymoGenetics and Serono are developing TACI-Ig for the treatment of autoimmune diseases and B-cell malignancies. TACI-Ig is a soluble receptor that binds to BLyS and APRIL, TNF family cytokines that promote B-cell survival and the production of harmful autoantibodies, which cause certain autoimmune diseases such as systemic lupus erythematosus (SLE). Current data indicates that levels of BLyS and APRIL are elevated in patients with rheumatoid arthritis, SLE and B-cell malignancies. TACI-Ig has been shown to affect several stages of B-cell development and may inhibit the survival of cells responsible for making antibodies. ZymoGenetics is developing TACI-Ig in collaboration with Serono S.A. and is conducting clinical studies in patients with SLE, rheumatoid arthritis and advanced B-cell malignancies, such as multiple myeloma, B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Commencing July 1, TACI-Ig will be referred to by its International Nonproprietary Name ‘atacicept’.

~~About RaptivaÒ~~###

~~Raptiva® (efalizumab) is a humanized therapeutic antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T~~Forward-~~cells~~looking ~~that lead to the development of psoriasis symptoms. Raptiva® is designed to be administered once weekly via subcutaneous injection and can be self-administered by patients at home.~~Statements

~~Raptiva® received~~For EU approval for the ‘Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporine, methotrexate and PUVA’.ZymoGenetics

~~Adverse~~This ~~events~~press release contains “forward-looking ~~observed~~statements” ~~with~~within ~~Raptiva® include~~the ~~headache,~~meaning ~~non~~of the Private Securities Litigation Reform Act of 1995. These forward-~~specific~~looking ~~infection~~statements are based on the current intent and (eexpectations of the management of ZymoGenetics.g These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict., ~~common~~ZymoGenetics’ ~~colds),~~actual ~~chills,~~results ~~pain~~and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, ~~nausea~~preclinical and clinical development, ~~asthenia~~regulatory ~~(weakness)~~oversight, intellectual property claims and ~~fever,~~litigation ~~all~~and other risks detailed in the ofcompany’s ~~which~~public ~~diminished~~filings ~~after~~with the ~~first~~Securities 1and Exchange Commission, including the company’s Annual Report on Form 10-2K ~~doses~~for the year ended December 31, 2005. ~~There~~Except isas required by law, ZymoGenetics undertakes no ~~evidence~~obligation ofto ~~accumulation~~update any forward-looking or ~~cumulative~~other ~~toxicity~~statements toin ~~date~~this press release, whether as a result of new information, future events or otherwise.

~~Serono~~For has the rights to develop and market Raptiva® worldwide outside of the United States and Japan. To date, RaptivaÒ is available in over 50 countries, amongst them many countries in Europe, Latin America, Asia as well as Australia. Development and marketing rights in the United States, where RaptivaÒ has been available since November 2003, remain with Genentech Inc. (NYSE:DNA) and its U.S. partner XOMA (Nasdaq: XOMA).Serono

~~About~~Some ~~Psoriasis~~of the statements in this press release are forward looking. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Serono S.A. and affiliates to be materially different from those expected or anticipated

~~Psoriasis~~(2) Characterizing the isrelationship abetween TTACI-~~cell~~Ig ~~mediated~~exposure ~~disease,~~and ~~which occurs when skin cells grow abnormally~~IgG, ~~resulting~~ inIgM ~~thick,~~and ~~red,~~IgA ~~scaly,~~antibody ~~inflamed~~response ~~patches. Plaque psoriasis, the most~~in ~~common~~patients ~~form~~with ofrheumatoid ~~the~~arthritis ~~disease is characterized by inflamed patches of skin~~ (~~“lesions”~~RA) ~~topped~~; ~~with~~(abstract ~~silvery~~FRI0157), ~~white~~7th Annual ~~scales.~~European ~~Psoriasis~~Congress ~~can be limited to a few spots or involve extensive areas~~ of ~~the body~~Rheumatology (EULAR), ~~appearing~~June 21 ~~most~~— ~~commonly on the knees~~24, ~~elbows,~~ ~~trunk~~2006, ~~and scalp. Although it is highly visible~~Amsterdam, ~~psoriasis is not a contagious disease. While there are a number of medications that may help control the symptoms of psoriasis, there currently is no known permanent cure.~~Netherlands

~~Background material~~2

~~For~~in the ~~free~~forward-looking Bstatements. Forward-~~roll,~~looking ~~video and~~statements ~~other~~are ~~content~~based ~~for~~on Serono’s current expectations and ~~its~~assumptions, ~~products~~which may be affected by a number of factors, ~~please~~including ~~visit~~those ~~the~~discussed ~~Serono~~in ~~Media~~this press release and more fully ~~Center~~described ~~www.thenewsmarket.com/~~in Serono.’s ~~You~~Annual ~~can~~Report ~~download~~on ~~print~~Form 20-~~quality~~F ~~images~~filed with the U.S. Securities and Exchange Commission on February 28, 2006. These factors include any failure or delay in Serono’s ability to develop new products, any failure to receive anticipated ~~broadcast-standard~~regulatory ~~video~~approvals, ~~digitally~~any problems in commercializing current products as a result of competition or byother ~~tape~~factors, ~~from~~our ~~this~~ability ~~site.~~to obtain ~~Registration~~reimbursement coverage for our products, the outcome of government investigations and ~~video~~litigation isand ~~free~~government regulations limiting our ability to sell our products. Serono has no responsibility to update the forward-looking ~~media~~statements contained in this press release to reflect events or circumstances occurring after the date of this press release.

###

About ZymoGenetics

ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of potential proprietary product candidates that are moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit www.zymogenetics.com.

About Serono

Serono is a global biotechnology leader. The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel®/Ovitrelle®, Serostim®, Saizen®, Zorbtive™ and Raptiva®. In addition to being the world leader in reproductive health, Serono has strong market positions in neurology, metabolism and growth and has recently entered the psoriasis area. The Company’s research programs are focused on growing these businesses and on establishing new therapeutic areas, including oncology and autoimmune diseases. Currently, there are more than 25 on-going development projects.

In 2005, Serono, whose products are sold in over 90 countries, achieved worldwide revenues of US$2,586.4 million. Reported net loss in 2005 was US$106.1 million, reflecting a charge of US$725 million taken relating to the settlement of the US Attorney’s Office investigation of Serostim. Excluding this charge as well as other non-recurring items, adjusted net income grew 28.4% to US$565.3 million in 2005. Bearer shares of Serono S.A., the holding company, are traded on the virt-x (SEO) and its American Depositary Shares are traded on the New York Stock Exchange (SRA).

###

Some of the statements in this press release are forward looking. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Serono S.A. and affiliates to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements are based on Serono’s current expectations and assumptions, which may be affected by a number of factors, including those discussed in this press release and more fully described in Serono’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on February 28, 2006. These factors include any failure or delay in Serono’s ability to develop new products, any failure to receive anticipated regulatory approvals, any problems in commercializing current products as a result of competition or other factors, our ability to obtain reimbursement coverage for our products, the outcome of government investigations and litigation and government regulations limiting our ability to sell our products. Serono has no responsibility to update the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release.

###

For more information, please contact:

Corporate Media Relations:	Corporate Investor Relations:	~~Corporate Investor Relations:~~
Tel:+41 22 739 36 00	Tel:+41 22 739 36 01	~~Tel:~~	~~+41 22 739 36 01~~
Fax:+41 22 739 30 85	Fax:+41 22 739 30 22	~~Fax:~~	~~+41 22 739 30 22~~
http://www.serono.com	Reuters: SEO.VX / SRA.N	~~Reuters: SEO.VX / SRA.N~~
	Bloomberg: SEO VX / SRA US	~~Bloomberg: SEO VX / SRA US~~
		Investor Relations, USA:
Media Relations, USA:	Investor Relations, USA:
		Tel:	+1 781 681 2552
Tel:+1 781 681 2340	Tel:+1 781 681 2552
		Fax:	+1 781 681 2912
Fax:+1 781 681 2935	Fax:+1 781 681 2912
http://www.seronousa.com
ZymoGenetics
Investor Relations		Media Relations
John Calhoun, MD, MBA		Susan W. Specht, MBA
Director, Corporate Communications & Investor Relations		Associate Director, Corporate Communications
(206) 442-6744		(206) 442-6592

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SERONO S.A.,		~~SERONO S.A.,~~
	a Swiss corporation		~~a Swiss corporation~~
	(Registrant)		~~(Registrant)~~
Date	June 22, 2006		By:	/s/ Stuart Grant
Date June 26, 2006	By:	/s/ Stuart Grant
	Name:	Stuart Grant	~~Name:~~	~~Stuart Grant~~
	Title:	Chief Financial Officer	~~Title:~~	~~Chief Financial Officer~~

Filing Compare · MERCK SERONO S.A.